Sign Out
Dosage in adults: See Table 2.
Click on icon to see table/diagram/imageDosage in children: Film-coated tablet: See Table 3.
Click on icon to see table/diagram/imageZINNAT tablets should not be crushed or split and are therefore unsuitable for treatment of patients, such as younger children, who cannot swallow whole tablets. Therefore, ZINNAT suspension is recommended for patients who cannot swallow whole tablets.
When doses below 250 mg are required, ZINNAT FOR SUSPENSION 125mg/5ml should be used.
There is no experience of using ZINNAT in children under the age of 3 months.
Granules for oral suspension: There is no clinical trial data available on the use of ZINNAT in children under the age of 3 months. (See Table 4.)
Click on icon to see table/diagram/imageThe following two tables serve as a guideline for simplified administration from measuring spoons (5ml) for the 125mg/5ml or the 250mg/5ml multidose suspension, and 125mg or 250mg single dose sachets. (See Tables 5 and 6.)
Click on icon to see table/diagram/image
Click on icon to see table/diagram/imageTo enhance compliance and improve the dosing accuracy in very young children, a dosing syringe can be supplied with a multidose bottle containing 50ml of suspension. However, dosing in spoonfuls should be considered a more favourable option if the child is able to take the medication from the spoon.
If required, the dosing syringe may also be used in older children (refer to the dosing tables as follows).
The recommended doses for the paediatric dosing syringe are expressed in ml or mg and according to body weight in the following tables. (See Tables 7 and 8.)
Click on icon to see table/diagram/image
Click on icon to see table/diagram/imageDosage in renal impairment: Cefuroxime is primarily excreted by the kidneys. In patients with markedly impaired renal function, it is recommended that the dosage of cefuroxime be reduced to compensate for its slower excretion (see Table 9 as follows).
Click on icon to see table/diagram/image